EGRX vs. LTRN, MURA, CELU, IMMX, HCWB, EQ, KZR, MNOV, SCYX, and RLYB
Should you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Lantern Pharma (LTRN), Mural Oncology (MURA), Celularity (CELU), Immix Biopharma (IMMX), HCW Biologics (HCWB), Equillium (EQ), Kezar Life Sciences (KZR), MediciNova (MNOV), SCYNEXIS (SCYX), and Rallybio (RLYB). These companies are all part of the "pharmaceutical preparations" industry.
Eagle Pharmaceuticals (NASDAQ:EGRX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Eagle Pharmaceuticals has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eagle Pharmaceuticals' return on equity of 0.00% beat Lantern Pharma's return on equity.
Eagle Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
Eagle Pharmaceuticals received 400 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 70.79% of users gave Eagle Pharmaceuticals an outperform vote.
In the previous week, Lantern Pharma had 6 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 7 mentions for Lantern Pharma and 1 mentions for Eagle Pharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.59 beat Lantern Pharma's score of 0.06 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.
Eagle Pharmaceuticals currently has a consensus target price of $17.00, suggesting a potential upside of 308.65%. Given Eagle Pharmaceuticals' higher possible upside, research analysts plainly believe Eagle Pharmaceuticals is more favorable than Lantern Pharma.
Summary
Eagle Pharmaceuticals beats Lantern Pharma on 11 of the 15 factors compared between the two stocks.
Get Eagle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eagle Pharmaceuticals Competitors List
Related Companies and Tools
